We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-16.95%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.4B
AUM Growth
-$286M
Cap. Flow
-$9.42M
Cap. Flow %
-0.67%
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$130M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56M
3
SRRK icon
Scholar Rock
SRRK
+$50M
4
VERA icon
Vera Therapeutics
VERA
+$45.8M
5
NUVL
Nuvalent
NUVL
+$37.1M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$120M
2
MRK icon
Merck
MRK
+$79.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$52.8M
5
SLNO
Soleno Therapeutics
SLNO
+$47.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
51
DELISTED
Ventyx Biosciences
VTYX
$2.3M 0.16%
2,000,000
– –
ARCT icon
52
Arcturus Therapeutics
ARCT
$211M
$2.24M 0.16%
+211,790
New +$3.36M
PASG icon
53
Passage Bio
PASG
$14.1M
$2.15M 0.15%
305,000
– –
FATE icon
54
Fate Therapeutics
FATE
$326M
$1.99M 0.14%
2,515,850
+50,850
+2% +$62.3K
ANRO icon
55
Alto Neuroscience
ANRO
$1.11B
$1.98M 0.14%
915,000
– –
STRO icon
56
Sutro Biopharma
STRO
$421M
$1.69M 0.12%
260,000
+3,000
+1% +$47.2K
ENGN icon
57
enGene Therapeutics
ENGN
$121M
$1.66M 0.12%
370,000
– –
ALEC icon
58
Alector
ALEC
$199M
$621K 0.04%
+504,540
New +$821K
ATRA icon
59
Atara Biotherapeutics
ATRA
$76.1M
$559K 0.04%
94,085
-30,915
-25% -$270K
TRAW icon
60
Traws Pharma
TRAW
$8.1M
$403K 0.03%
175,000
+100,000
+133% +$520K
MGNX icon
61
MacroGenics
MGNX
$257M
$356K 0.03%
280,000
– –
TENX icon
62
Tenax Therapeutics
TENX
$503M
$350K 0.03%
53,439
-1,750
-3% -$11.2K
CNTA
63
DELISTED
Centessa Pharmaceuticals
CNTA
$214K 0.02%
+14,888
New +$244K
A icon
64
Agilent Technologies
A
$41.2B
– –
-75,000
Closed -$10.1M
ALLO icon
65
Allogene Therapeutics
ALLO
$694M
– –
-1,500,000
Closed -$3.19M
AZN icon
66
AstraZeneca
AZN
$250B
– –
-237,500
Closed -$31.1M
BHC icon
67
Bausch Health
BHC
$2.34B
– –
-250,000
Closed -$2.02M
BMRN icon
68
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-860,000
Closed -$56.5M
GLUE icon
69
Monte Rosa Therapeutics
GLUE
$1.35B
– –
-425,000
Closed -$2.95M
GSK icon
70
GSK
GSK
$106B
– –
-1,000,000
Closed -$33.8M
IONS icon
71
Ionis Pharmaceuticals
IONS
$9.4B
– –
-595,000
Closed -$20.8M
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$16.7B
– –
-975,000
Closed -$120M
LEGN icon
73
Legend Biotech
LEGN
$4.01B
– –
-475,000
Closed -$15.5M
MDGL icon
74
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-95,000
Closed -$29.3M
MRK icon
75
Merck
MRK
$318B
– –
-800,000
Closed -$79.6M
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Vestal Point Capital held 86 positions worth $1.4B, down 17% from $1.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Vestal Point Capital's Q1 2025 filing shows 13 new, 27 increased, 13 reduced and 23 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M. The largest sale was Jazz Pharmaceuticals, an estimated $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vestal Point Capital's largest Q1 2025 buy was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M.
  • Vestal Point Capital added most to Arcellx in Q1 2025, an estimated $130M increase.
  • Vestal Point Capital's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $52.8M.
  • Vestal Point Capital fully exited Jazz Pharmaceuticals in Q1 2025, selling an estimated $120M.
  • Vestal Point Capital's ten largest holdings make up 51% of its $1.4B portfolio in Q1 2025.
  • Vestal Point Capital opened 13 new positions and closed 23 in Q1 2025.
  • Vestal Point Capital's portfolio value fell 17% quarter-over-quarter to $1.4B.

Based on Vestal Point Capital's 13F filing for Q1 2025, filed 15 May 2025.